Denkert C et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021;22(8):1151-61. Abstract
Lambein K et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: Clinical and pathobiological relevance. Am J Clin Pathol 2013;140(4):561-6. Abstract
Modi S et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study. J Clin Oncol 2020;38(17):1887-96. Abstract
Nakada T et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo) 2019;67(3):173-85. Abstract
Pistilli B et al. Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i). ASCO 2020;Abstract 1037.
Saura C et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. ASCO 2018;Abstract 1014.
Schettini F et al. Clinical, pathological and gene expression features of HER2-low breast cancer. ESMO 2020;Abstract 23P.
Tarantino P et al. HER2-low breast cancer: Pathological and clinical landscape. J Clin Oncol 2020;38(17):1951-62. Abstract
Wang J et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. ASCO 2021;Abstract 1022.